Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Casdatifan (Primary) ; Volrustomig (Primary)
  • Indications Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms ARC-20
  • Sponsors Arcus Biosciences

    • Most Recent Events

    • 06 Nov 2024 Results (n=17; as of 23 April 2024) presented in an Arcus Biosciences Media Release.
    • 06 Nov 2024 According to an Arcus Biosciences media release, 100mg (50mg twice daily (BID), capsules) and 50mg expansion cohorts: Updated data, including median PFS, are expected to be presented in the first quarter of 2025. 150mg and 100mg (once daily (QD), tablets) expansion cohorts: Initial data are expected to be presented in 2025.and 100mg of casdatifan plus cabozantinib: Safety data are expected to be presented in 2025.
    • 06 Nov 2024 According to an Arcus Biosciences media release, Multiple expansion cohorts of this study evaluating casdatifan in ccRCC as a monotherapy and in combination with cabozantinib in ccRCC are underway with additional data presentations expected in the next 12 months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top